BRAF and melanoma: The lack of overall survival benefit of combination CPIs versus anti-PD-1 monotherapy in all-comer patients [3, 69, 77] suggests the latter, although careful consideration of subgroups (e.g. BRAF mutant melanomas, PD-L1 < 1%) [3, 76] may enrich for some patients more likely to benefit from first-line combination.